Sugi Predict

Sugi Predict / Compounds / SCHEMBL855843

SCHEMBL855843

SCHEMBL855843

CC1(C)OB(c2cnc(N)cc2C(F)(F)F)OC1(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 14/20 0.36
▸ PIK3CA P42336 13/20 0.36
▸ PIK3CD O00329 3/20 0.35
▸ PIK3C2B O00750 2/20 0.35
▸ PIK3R1 P27986 2/20 0.35
▸ PIK3CB P42338 2/20 0.35
▸ PIK3CG P48736 2/20 0.35
▸ PRKDC P78527 2/20 0.35
▸ PIK3C3 Q8NEB9 2/20 0.35
▸ PI4KB Q9UBF8 2/20 0.35
▸ RICTOR Q6R327 1/20 0.35
▸ RPTOR Q8N122 1/20 0.35
▸ MAPKAP1 Q9BPZ7 1/20 0.35
▸ MLST8 Q9BVC4 1/20 0.35
▸ PDGFRB P09619 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ LIPE Q05469 2/20 0.33
▸ AKR1C3 P42330 1/20 0.33
▸ PIK3R5 Q8WYR1 1/20 0.33
▸ EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434913 1.00 MTOR (0.36) MTORPIK3CAPIK3CDPIK3C2BPIK3R1
SCHEMBL24575389 0.83 LIPE (0.33) LIPE
SCHEMBL14468860 0.82 LIPE (0.35) PDGFRBKDRLIPE
SCHEMBL20798797 0.82 PIK3CA (0.36) MTORPIK3CAPIK3CDPIK3C2BPIK3R1
SCHEMBL17859814 0.81 CYP3A4 (0.40) PIK3R1PDGFRBKDRLIPEEGFR
SCHEMBL2814938 0.80 LPL (0.34) PDGFRBKDREGFR
SCHEMBL2818121 0.80 NOS3 (0.33) PDGFRBKDRLIPEEGFR
SCHEMBL25428075 0.79 LIPE (0.37) LIPEEGFR
SCHEMBL13016581 0.79 NOS3 (0.35) PDGFRBKDR
SCHEMBL22606823 0.78 LPL (0.36) LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 — — US disclosed
CN-117777042-B Triazine hydroxamic acid derivative and preparation method and application thereof 长沙医学院 2025-01-24 — — CN disclosed
CN-117777042-A Triazine hydroxamic acid derivative and preparation method and application thereof 长沙医学院 2024-03-29 — — CN disclosed
US-11572359-B2 PARP/PI3K double-target inhibit containing pyridopyrimidine structure CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-02-07 — — US disclosed
US-11548867-B2 Amido compounds as AhR modulators IDEA YA BIOSCIENCES, INC. (US) 2023-01-10 — — US disclosed
CN-113045582-B PARP-1/PI3K double-target inhibitor or pharmaceutically acceptable salt thereof, and preparation method and application thereof 中国药科大学 2022-12-23 — — CN disclosed
CN-109810100-B Benzofuran-containing PARP-1 and PI3K dual-target inhibitors 中国药科大学 2022-03-11 — — CN disclosed
EP-3475285-B1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS INC (CN) 2022-02-09 — — EP disclosed
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2022-02-08 — — US disclosed
CN-109810098-B PARP-1 and PI3K dual-target inhibitor containing phthalazin-1 (2H) -one structure 中国药科大学 2021-08-31 — — CN disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 — — US disclosed
EP-2118087-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-11-18 — — EP disclosed
EP-1989201-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2008-11-12 — — EP disclosed
EP-1984350-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS Novartis AG (CH) 2008-10-29 — — EP disclosed
WO-2008098058-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2008-08-14 — — WO disclosed
WO-2008098058-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2008-08-14 — — WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572359-B2 PARP/PI3K double-target inhibit containing pyridopyrimidine structure PARP2, PARP1, PIK3CA MTOR 74/4885PIK3CA 3/4885PIK3CD 9/4885
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof MTOR, RPTOR, RICTOR MTOR 1/4885PIK3CA 20/4885PIK3CD 27/4885
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE PI4KA, PI4KB, PI4K2A MTOR 64/4885PIK3CA 5/4885PIK3CD 7/4885
US-11548867-B2 Amido compounds as AhR modulators AHR, ARNT, RXRB MTOR 3684/4885PIK3CA 4470/4885PIK3CD 4807/4885
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3C2B, PIK3C2A, PIK3R1 MTOR 18/4885PIK3CA 10/4885PIK3CD 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.